Trimel Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:TRLPF)

$0.24 0.00 (1.27 %)
(As of 12/17/2017 08:42 AM ET)
Previous Close$0.24
Today's Range$0.24 - $0.24
52-Week Range$0.08 - $0.40
Volume5,735 shs
Average Volume33,054 shs
Market Capitalization$50.94 million
P/E RatioN/A
Dividend YieldN/A

About Trimel Pharmaceuticals (OTCMKTS:TRLPF)

Trimel Pharmaceuticals logoTrimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, was approved for sale in the United States by the FDA in May 2014. It is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children. Trimel is also developing Tefina™, a use-as-required testosterone nasal gel for the treatment of female orgasmic disorder. Tefina™ has completed a number of clinical studies, including a large Phase II trial in April 2014, where the product positively showed statistical significance and was found to be well-tolerated. In July 2014, Trimel acquired the Canadian rights to Estrace® (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms.

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity Ratio0.20%
Current Ratio1.81%
Quick Ratio0.94%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.49 million
Price / Sales2.08
Cash Flow$0.06 per share
Price / Cash3.84
Book Value$0.06 per share
Price / Book3.98


Trailing EPS($0.03)
Net Income$11.11 million
Net Margins-103.61%
Return on Equity-61.59%
Return on Assets-26.53%


Outstanding Shares213,120,000

Trimel Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions

What is Trimel Pharmaceuticals' stock symbol?

Trimel Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Trimel Pharmaceuticals' earnings last quarter?

Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) issued its quarterly earnings results on Wednesday, March, 18th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. Trimel Pharmaceuticals had a negative return on equity of 61.59% and a negative net margin of 103.61%. View Trimel Pharmaceuticals' Earnings History.

When will Trimel Pharmaceuticals make its next earnings announcement?

Trimel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Trimel Pharmaceuticals.

Who are some of Trimel Pharmaceuticals' key competitors?

How do I buy Trimel Pharmaceuticals stock?

Shares of Trimel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trimel Pharmaceuticals' stock price today?

One share of Trimel Pharmaceuticals stock can currently be purchased for approximately $0.24.

How big of a company is Trimel Pharmaceuticals?

Trimel Pharmaceuticals has a market capitalization of $50.94 million and generates $24.49 million in revenue each year. The specialty pharmaceutical company earns $11.11 million in net income (profit) each year or ($0.03) on an earnings per share basis. Trimel Pharmaceuticals employs 17 workers across the globe.

How can I contact Trimel Pharmaceuticals?

Trimel Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]

MarketBeat Community Rating for Trimel Pharmaceuticals (TRLPF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about Trimel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trimel Pharmaceuticals (OTCMKTS:TRLPF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Trimel Pharmaceuticals (OTCMKTS:TRLPF) Consensus Price Target History

Price Target History for Trimel Pharmaceuticals (OTCMKTS:TRLPF)

Trimel Pharmaceuticals (OTCMKTS:TRLPF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
3/22/2017Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 12/17/2015 forward)


Trimel Pharmaceuticals (OTCMKTS:TRLPF) Earnings History and Estimates Chart

Earnings by Quarter for Trimel Pharmaceuticals (OTCMKTS:TRLPF)

Trimel Pharmaceuticals (OTCMKTS TRLPF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2015($0.01)($0.01)ViewN/AView Earnings Details
3/18/2015($0.02)($0.04)ViewN/AView Earnings Details
11/7/2014($0.02)($0.02)ViewN/AView Earnings Details
6/17/2014($0.04)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Trimel Pharmaceuticals (OTCMKTS:TRLPF) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Trimel Pharmaceuticals (OTCMKTS:TRLPF)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Trimel Pharmaceuticals (OTCMKTS TRLPF)

No insider trades for this company have been tracked by


Trimel Pharmaceuticals (OTCMKTS TRLPF) News Headlines

Trimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngineTrimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngine - December 3 at 6:30 AM
Trimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngineTrimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngine - November 28 at 12:36 AM
Trimel reports 3Q lossTrimel reports 3Q loss - November 7 at 12:21 PM
Trimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on TuesdayTrimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on Tuesday - November 1 at 10:49 AM
Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on FridayTrimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on Friday - August 5 at 9:06 AM

SEC Filings

Trimel Pharmaceuticals (OTCMKTS:TRLPF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Trimel Pharmaceuticals (OTCMKTS TRLPF) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.